This brand-new training course will provide you with the insights and tools required to communicate a compelling commercial opportunity in a business plan and pitch that a team can unite behind and that prospective investors can support.
You are encouraged to bring a technology opportunity that you are working on (and may commercialise now or in the future) and to work on this throughout the day.
Open to academics, researchers, clinicians and industry representatives, the one day course will cover:
- Diagnosing your technology opportunity
- Identifying gaps in your opportunity and how to address potential issues
- What is a value milestone?
- An overview of the business planning process
- Pitching your idea to investors
- Examining a successful MedTech start-up case study – from technology to first revenue.
By the end of the day you will:
- Understand how to diagnose a technology opportunity in detail including looking at unmet needs, barriers and solutions
- Be able to understand and identify key value milestones along the commercialisation roadmap
- Understand how to manage and mitigate risk
- Use your own technology opportunity to create a business plan
- Understand how to formulate a compelling pitch to investors.
This course is free to staff and postgraduate research students at Translate partner universities (Bradford, Huddersfield, Leeds, Leeds Beckett, Sheffield Hallam and York). Places for industry and clinical representatives are available at a cost of £300, please email Mohua Siddique to secure your ticket. Spaces are limited and registration is essential.
The training course will be run by Nicholas Duggan, Viadynamics
About the trainer
Nicholas is an innovation and marketing professional with extensive experience across the medical technology, consumer products, financial services, and ICT sectors. He is a Partner at Viadynamics, a leading innovation and venturing agency.
Nicholas is also a founder and former CEO of Cellesce, a start-up company that aims to transform drug discovery and personalised medicine in the fight against cancer.
As CEO, he led the company through successful technology development, IP protection, building out the team, raising seed funding and two subsequent equity raising rounds, to the winning of first customers.